Effect of triacontanol on the pharmacokinetics of docetaxel in rats associated with induction of cytochrome P450 3A1/2

References

• Aneiros E, Mas R, Calderón B, et al. (1995). Effects of policosanol in lowering cholesterol level in patients with type II hypercholesterolemia. Curr Ther Res 56:176–81
   Google Scholar
• Arruzazabala ML, Carbajal D, Más R, et al. (1992). Effects of policosanol in Platelet aggregation in rats. Thromb Res 69:321–7
   Google Scholar
• Arruzazabala ML, Molina V, Mas R, et al. (2002). Antiplatelet effect of policosanol (20 and 40 mg/day) in healthy volunteers and dyslipidemic patients. Clin Exp Pharmacol Physiol 29:891–7
   PubMedGoogle Scholar
• Bruno R, Vivier N, Vergniol JC, et al. (1996). A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 24:153–72
   PubMedGoogle Scholar
• Debri K, Boobis AR, Davies DS, et al. (1995). Distribution and induction of CYP3A1 and CYP3A2 in rat liver and extrahepatic tissues. Biochem Pharmacol 50:2047–56
   PubMed Web of Science ®Google Scholar
• Dullens SP, Mensink RP, Bragt MC, et al. (2008). Effects of emulsified policosanols with different chain lengths on cholesterol metabolism in heterozygous LDL receptor-deficient mice. J Lipid Res 49:790–6
   PubMed Web of Science ®Google Scholar
• Fan XE, Zhang RW, Cheng HJ (2011). Use of triacontanol in preparation of medicaments for treatment of cancers. U.S. Patent 786,333,7B2
   Google Scholar
• Ferlay J, Shin HR, Bray F. (2010). Estimates of world-wide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–917
   PubMed Web of Science ®Google Scholar
• Gibson GG, Skett P. (1994). Introduction to drug metabolism. 2nd edn. London: Blackie Academic and Professional, p. 217
   Google Scholar
• Gouni-Berthold I, Berthold HK. (2002). Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 143:356–65
   PubMed Web of Science ®Google Scholar
• Guengerich FP. (1999). Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1–17
   PubMed Web of Science ®Google Scholar
• Guo H, Liu C, Li J, et al. (2013). A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug–drug interactions. J Pharm Sci 102:2819–36
   PubMed Web of Science ®Google Scholar
• Hargrove JL, Greenspan P, Hartle DK. (2004). Nutritional significance and metabolism of very long chain fatty alcohols and acids from dietary waxes. Exp Biol Med 229:215–26
   PubMed Web of Science ®Google Scholar
• Hudachek SF, Gustafson DL. (2013). Incorporation of ABCB1-mediated transport into a physiologically-based pharmacokinetic model of docetaxel in mice. J Pharmacokinet Pharmacodyn 40:437–49
   PubMedGoogle Scholar
• Huizing MT, Misser VH, Pieters RC, et al. (1995). Taxanes: a new class of antitumor agents. Cancer Investig 13:381–404
   PubMed Web of Science ®Google Scholar
• Khan KK, He YQ, Domanski TL, et al. (2002). Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol Pharmacol 61:495–506
   PubMed Web of Science ®Google Scholar
• Klener P. (1995). Taxanes – new class of antitumor chemotherapeutics [in Czech]. Remedia 5:154–60
   Google Scholar
• Kobayashi K, Urashima K, Shimada N, et al. (2002). Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat. Biochem Pharmacol 63:889–96
   PubMed Web of Science ®Google Scholar
• Li L, Chen XH, Bi KS, et al. (2011). Study on plasma concentration and pharmacokinetics of docetaxel in rats by LC-MS/MS. China Pharm 22:398–401
   Google Scholar
• Li L, Li Z, Deng C, et al. (2012). A mechanism-based Pharmacokinetic pharmacodynamic model for CYP3A1/2 induction by dexamethasone in rats. Acta Pharm Sinica 33:127–36
   Google Scholar
• Li T, Li N, Guo Q, et al. (2011). Inhibitory effects of wogonin on catalytic activity of cytochromeP450 enzyme in human liver microsomes. Eur J Drug Metab Pharmacokinet 36:249–56
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCт method. Methods 25:402–8
   PubMed Web of Science ®Google Scholar
• Marre F, Sanderink GJ, de Sousa G, et al. (1996). Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 56:1296–302
   PubMed Web of Science ®Google Scholar
• Martínez-Jiménez CP, Jover R, Donato MT, et al. (2007). Transcriptional regulation and expression of CYP3A4 in hepatocytes. Curr Drug Metab 8:185–94
   PubMed Web of Science ®Google Scholar
• Mei Q, Richards K, Strong-Basalyga K, et al. (2004). Using real-time quantitative TaqMan RT-PCR to evaluate the role of dexamethasone in gene regulation of rat P-glycoproteins mdr1a/1b and cytochrome P450 3A1/2. J Pharm Sci 93:2488–96
   PubMed Web of Science ®Google Scholar
• Menendez R, Fragá V, Amor AM, et al. (1997). Oral administration of policosanol inhibits in vitro copper-induced rat lipoprotein lipid peroxidation. Physiol Behav 67:1–7
   Google Scholar
• Miles D, von Minckwitz G, Seidman AD. (2002). Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist 7:13–19
   PubMed Web of Science ®Google Scholar
• Pan J, Xiang Q, Renwick AB, et al. (2002). Use of a quantitative real-time reverse transcription-polymerase chain reaction method to study the induction of CYP1A, CYP2B and CYP4A forms in precision-cut rat liver slices. Xenobiotica 32:739–47
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Onetto N, Canetta RM, et al. (1992). Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 19:646–62
   PubMed Web of Science ®Google Scholar
• Royer I, Monsarrat B, Sonnier M, et al. (1996). Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 56:58–65
   PubMed Web of Science ®Google Scholar
• Shibayama Y, Ushinohama K, Ikeda R, et al. (2006). Blackwell Publishing Asia Effect of methotrexate treatment on expression levels of multidrug resistance protein 2, breast cancer resistance protein and organic anion transporters Oat1, Oat2 and Oat3 in rats. Cancer Sci 97:1260–6
   PubMed Web of Science ®Google Scholar
• Singh DK, Li L, Porter TD. (2006). Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase. J Pharmacol Exp Ther 318:1020–26
   PubMed Web of Science ®Google Scholar
• Telhada MB, Pereira TM, Lechner MC. (1992). Effect of dexamethasone and phenobarbital on run-on transcription rate and CYP3A mRNA concentration in rat liver changes during development. Arch Biochem Biophys 298:715–25
   PubMed Web of Science ®Google Scholar
• Tettey JN, Maggs JL, Rapeport WG, et al. (2001). Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. Chem Res Toxicol 14:965–74
   PubMed Web of Science ®Google Scholar
• Tkaczuk KH. (2009). Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. Clin Ther 31:2273–89
   PubMed Web of Science ®Google Scholar
• Wang X, Song L, Li N, et al. (2013). Pharmacokinetics and biodistribution study of paclitaxel liposome in Sprague-Dawley rats and Beagle dogs by liquid chromatography-tandem mass spectrometry. Drug Res 63:603--6
   Google Scholar
• Yamamoto N, Tamura T, Kamiya Y, et al. (2000). Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J Clin Oncol 18:2301–08
   PubMed Web of Science ®Google Scholar
• Yu L, Lu S, Zhao N, et al. (2008). Male-specific induction of CYP3A2 in rats by zolmitriptan. J Pharm Pharmacol 60:1601–7
   PubMed Web of Science ®Google Scholar
• Zhang Q, Xu HH, Zhou F, et al. (2008). Acute toxicity detection of pesticide triacontanol. J Zhengzhou Univ 43:364–6
   Google Scholar
• Zhang ZY, Pelletier RD, Wong YN, et al. (2006). Preferential inducibility of CYP1A1 and CYP1A2 by TCDD: differential regulation in primary human hepatocytes versus transformed human cells. Biochem Biophys Res 341:399–407
   PubMed Web of Science ®Google Scholar